Tweet
Copied from Contact Lenses Today
http://www.cltoday.com/issues/CLToday_102509.htm
Auxano Diagnostics Developing a New Point-of-Care Indicator System for Dry Eye Syndrome
Auxano Diagnostics, LLC, a subsidiary of Auxano Biomedical, LLC, announced the application of the company's breakthrough wound care technology to the treatment of dry eye syndrome (DES) with the Auxano point-of-care indicator system. Brian Windsor, PhD, Chief Technical Officer for Auxano Biomedical, said, "We are excited that the advances of our wound care technology can be applied to the treatment of DES and other ophthalmic diseases. Our point-of-care indicator system has the potential to provide earlier and more accurate guidance to millions of DES sufferers."
Auxano's system is a rapid point-of-care diagnostic indicator for ophthalmic inflammatory diseases and has the potential to provide for accurate indications of DES within minutes, according to the company. The company has developed a similar point-of-care product for wound care that is based on the efficient and accurate detection of active enzymes in biological samples. This MMP indicator is in clinical trials through a partnership with a global technology company with the expectation of a CE mark in December 2009, followed by FDA 510(k) approval.
Auxano's primary focus is the adaptation, optimization and commercialization of the existing technology for acute and chronic inflammatory diseases of the eye, in particular, dry eye syndrome. Initial data indicates positive results for detecting physiologically relevant MMP levels in dry eye syndrome.
Auxano Diagnostics and Auxano Biomedical are portfolio companies of Emergent Technologies, Inc. For more information on Emergent Technologies, Inc., visit www.etibio.com.
http://www.cltoday.com/issues/CLToday_102509.htm
Auxano Diagnostics Developing a New Point-of-Care Indicator System for Dry Eye Syndrome
Auxano Diagnostics, LLC, a subsidiary of Auxano Biomedical, LLC, announced the application of the company's breakthrough wound care technology to the treatment of dry eye syndrome (DES) with the Auxano point-of-care indicator system. Brian Windsor, PhD, Chief Technical Officer for Auxano Biomedical, said, "We are excited that the advances of our wound care technology can be applied to the treatment of DES and other ophthalmic diseases. Our point-of-care indicator system has the potential to provide earlier and more accurate guidance to millions of DES sufferers."
Auxano's system is a rapid point-of-care diagnostic indicator for ophthalmic inflammatory diseases and has the potential to provide for accurate indications of DES within minutes, according to the company. The company has developed a similar point-of-care product for wound care that is based on the efficient and accurate detection of active enzymes in biological samples. This MMP indicator is in clinical trials through a partnership with a global technology company with the expectation of a CE mark in December 2009, followed by FDA 510(k) approval.
Auxano's primary focus is the adaptation, optimization and commercialization of the existing technology for acute and chronic inflammatory diseases of the eye, in particular, dry eye syndrome. Initial data indicates positive results for detecting physiologically relevant MMP levels in dry eye syndrome.
Auxano Diagnostics and Auxano Biomedical are portfolio companies of Emergent Technologies, Inc. For more information on Emergent Technologies, Inc., visit www.etibio.com.